Targeted Radionuclide Therapy of Human Tumors.
Targeted Radionuclide Therapy of Human Tumors.
复制标题
DOI：
10.3390/ijms17010033
复制
发表时间：
2015-12-28
影响因子：
5.6
通讯作者：
Zvyagin AV
中科院分区：
文献类型：
--
作者：
Gudkov SV;Shilyagina NY;Vodeneev VA;Zvyagin AV
放射性核素靶向治疗是核医学发展最活跃的方向之一。与传统的外部射束治疗不同，靶向放射性核素治疗对正常组织造成较少的附带损伤，并允许靶向药物递送到临床诊断的肿瘤畸形以及转移的细胞和细胞簇，从而提供癌症的全身治疗。靶向放射性核素治疗的方法基于使用对肿瘤细胞表面上的抗原具有高亲和力的放射性核素的分子载体。由于癌症生物学、生物工程学和放射化学的知识基础不断扩大，靶向放射性核素治疗的潜力显着增长。本文就放射性核素治疗血液系统恶性肿瘤的进展及实体瘤的治疗方法作一综述。
Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.